Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice William C. ZamboniLaura L. JungJulie L. Eiseman PHASE II STUDIES 02 February 2008 Pages: 399 - 406
Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil Michael J. KelnerTrevor C. McMorrisPharnuk Suthipinijtham PRECLINICAL STUDIES 29 January 2008 Pages: 407 - 415
Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [3 H]-rolipram binding in guinea pig tissues Agnes L.-F. ChanHui-Lin HuangWun-Chang Ko PRECLINICAL STUDIES 09 February 2008 Pages: 417 - 424
Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by a new series of substituted-1,3,4-oxadiazole derivatives Akhilesh KumarSaritha S. D’SouzaBharathi P. Salimath PRECLINICAL STUDIES 29 January 2008 Pages: 425 - 435
Synthesis and in vitro antiproliferative activity against human cancer cell lines of novel 5-(4-methyl-benzylidene)-thiazolidine-2,4-diones S. ChandrappaS. B. Benaka PrasadK. S. Rangappa PHASE I STUDIES 13 May 2008 Pages: 437 - 444
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors Michael J. OvermanGauri VaradhacharyJames L. Abbruzzese PHASE I STUDIES 05 June 2008 Pages: 445 - 454
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors Patricia LoRussoElisabeth I. HeathMary Jo Pilat PHASE I STUDIES 24 June 2008 Pages: 455 - 462
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Andrew H. KoElizabeth DitoMargaret A. Tempero PHASE II STUDIES 01 April 2008 Pages: 463 - 471
Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma Dennis L. CarterLina AsmarRobert L. Reid PHASE II STUDIES 13 May 2008 Pages: 473 - 481
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer Johan VansteenkisteEric Van CutsemPatrick Schöffski PHASE II STUDIES 19 April 2008 Pages: 483 - 488